Despite Physicians' Conservative Attitude Towards Biosimilars, TNF-Alpha Inhibitors Stand to Lose $22 Billion in Sales

— A Webinar from Decision Resources

Based on our 2009 Industry Report Biosimilars: TNF-Alpha Inhibitors and Interferon-Alphas in Immune and Infectious Disease, Decision Resources is offering an exclusive webinar entitled Despite Physicians' Conservative Attitude Towards Biosimilars, TNF-Alpha Inhibitors Stand to Lose $22 Billion in Sales. Because this webinar will feature major report findings, it is ONLY available to purchasers of this report.

Please contact us to learn how you can purchase this report and attend the webinar.

Since the launch of the first biosimilar human growth hormone (hGH) in 2006, biosimilars have become increasingly important to pharmaceutical companies as they try to protect the revenue streams generated by their major brands. Previously, branded biologics were protected from the type of generic erosion that eventually faces all small-molecule therapies by the absence of an abbreviated regulatory pathway for approval of biosimilars. As regulatory agencies have now established—or are soon going to establish—pathways for approval of biosimilars, companies marketing major brands will need to consider a complicated and interdependent set of issues.

This webinar, presented by Decision Resources Analyst MaryEllen Klusacek, Ph.D., will answer the following questions:

• Will TNF-alphas continue to be a priority for payers in terms of reducing costs associated with biologics? Will patients currently taking branded biologics be allowed to continue using them? To what extent do payers expect patients to switch to biosimilars? How soon do they think this will occur?
• How do gastroenterologists and rheumatologists compare to physicians in other specialties when prescribing biosimilars? What motivates gastroenterologists and rheumatologists to use biosimilars? Do gastroenterologists and rheumatologists have different expectations for different branded TNF-alphas?
• To what extent will biosimilars erode brand sales? How does the expected brand erosion for TNF-alphas compare to that of other classes of biologics? What individual molecules will face the most competition/lose the most in sales?

Dr. Klusacek will conduct a live Q & A session after the presentation.

Registration

Despite Physicians' Conservative Attitude Towards Biosimilars, TNF-Alpha Inhibitors Stand to Lose $22 Billion in Sales

December 3, 2009 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this report and attend the webinar, please contact us using the information below.

Contact Us

In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2009 Decision Resources, Inc. All rights reserved.